ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Nuclear transcription factor (NF-κB) >IκB / IKK inhibitors >BAY 11-7082

BAY 11-7082

BAY 11-7082 Suppliers list
Company Name: ZHENGZHOU JIUYI TIME NEW MATERIALS CO,.LTD
Tel: +86-15225627621 +86-13213167925
Email: jiuyitime@fdachem.com
Products Intro: Product Name:BAY 11-7082
CAS:19542-67-7
Purity:99% Package:20kg;1.10;USD|10kg;3.30;USD|1kg;6.60;USD
Company Name: ATK CHEMICAL COMPANY LIMITED
Tel: +undefined-21-51877795
Email: ivan@atkchemical.com
Products Intro: Product Name:BAY 11-7082
CAS:19542-67-7
Purity:98% HPLC Package:5MG;10MG;50MG;100MG,1G,5G
Company Name: Biochempartner
Tel: 0086-13720134139
Email: candy@biochempartner.com
Products Intro: Product Name:Bay 11-7821
CAS:19542-67-7
Purity:98% HPLC LCMS Package:10G;20G
Company Name: career henan chemical co
Tel: +86-0371-86658258
Email: factory@coreychem.com
Products Intro: Product Name:BAY 11-7082
CAS:19542-67-7
Purity:98% Package:1KG;3USD
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Products Intro: Product Name:BAY 11-7082
CAS:19542-67-7
Purity:99.92% Package:5mg;43USD|10mg;52USD|25mg;97USD Remarks:REAGENT;FOR LABORATORY USE ONLY

BAY 11-7082 manufacturers

  • BAY 11-7082
  • BAY 11-7082 pictures
  • $43.00
  • 2026-07-27
  • CAS:19542-67-7
  • Purity: 98.32%
  • Supply Ability: 10g
  • BAY 11-7082
  • BAY 11-7082 pictures
  • $1.10
  • 2026-07-02
  • CAS:19542-67-7
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
  • BAY 11-7082
  • BAY 11-7082 pictures
  • 2026-06-30
  • CAS:19542-67-7
  • Min. Order: 1kg
  • Purity: 98%
  • Supply Ability: 1000kg
BAY 11-7082 Basic information
Background
Product Name:BAY 11-7082
Synonyms:BAY 11-7082;BAY 11-7821;(E)-3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE;(e)-3-(4-methylphenyl)sulfonylprop-2-enenitrile;CS-608;100824;Bay 11-7821(BAY 11-7082);BAY 11-7082 - CAS 19542-67-7 - Calbiochem
CAS:19542-67-7
MF:C10H9NO2S
MW:207.25
EINECS:
Product Categories:Cytokine signaling;Inhibitors;NF-kB
Mol File:19542-67-7.mol
BAY 11-7082 Structure
BAY 11-7082 Chemical Properties
Melting point 133-135℃
Boiling point 397.6±42.0 °C(Predicted)
density 1.237±0.06 g/cm3(Predicted)
storage temp. Keep in dark place,Inert atmosphere,2-8°C
solubility DMSO: 25 mg/mL, soluble
form solid
color white
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.
InChIInChI=1S/C10H9NO2S/c1-9-3-5-10(6-4-9)14(12,13)8-2-7-11/h2-6,8H,1H3/b8-2+
InChIKeyDOEWDSDBFRHVAP-KRXBUXKQSA-N
SMILESC(#N)/C=C/S(C1=CC=C(C)C=C1)(=O)=O
Safety Information
WGK Germany 3
RTECS UD1430000
HS Code 2926907090
Storage Class11 - Combustible Solids
MSDS Information
ProviderLanguage
SigmaAldrich English
BAY 11-7082 Usage And Synthesis
DescriptionBAY 11-7082 (19542-67-7)inhibits cytokine-induced IκB-α phosphorylation via inhibition of IκB Kinase which results in inhibition of NFκB .1 Inhibits anchorage-independent growth of mammary epithelial cells induced with 4-hydroxyestradiol via inhibition of NFκB activation.2 Inhibits IFNα production and blocks nuclear translocation of IRF7 in plasmacytoid dendritic cells.3 Facilitates wound healing by inhibiting TNFα-induced MMP expression.4 A useful tool for probing the involvement of NFκB in physiological and pathophysiological processes.5 Cell permeable.
UsesBay 11-7082 has been used as:
  • a nuclear factor-kappa B (NF-kB) inhibitor to verify the action of the NF-kB signaling pathway in the production of interleukin (IL)-8
  • a nuclear factor-kappa B (NF-kB) inhibitor to study the role of NF-kB activation in Mycoplasma hyorhinis -induced epithelial-mesenchymal transition (EMT) and cell migration
  • a nod-like receptor family pyrin domain containing 3 (NLRP3) selective inhibitor to examine its effects on liver inflammation in mice after hematopoietic stem cell transplantation

DefinitionChEBI: A nitrile that is acrylonitrile in which the hydrogen located beta,trans to the cyano group is replaced by a tosyl group. It is an inhibitor of cytokine-induced IkappaB-alpha phosphorylation i cells.
General DescriptionPotential anti-inflammatory agent that selectively and irreversibly inhibits the TNF-α-inducible phosphorylation of IκBα (IC50 = 10 μM), resulting in a decreased expression of NF-κB and of adhesion molecules. Does not affect constitutive IκBα autophosphorylation. Inhibits TNF-α-induced surface expression of the endothelial-leukocyte cell adhesion molecules E-selectin, VCAM-1, and ICAM-1. A 100 mM (10 mg/483 μl) solution of BAY 11-7082 (Cat. No. 196871) in DMSO is also available is also available.
Biological ActivityIrreversible inhibitor of TNF- α -stimulated I κ B α phosphorylation (IC 50 ~ 10 μ M); leads to decreased NF- κ B and subsequent decreased expression of adhesion molecules. Also reversibly activates MAP kinases and stimulates apoptosis.
Biochem/physiol ActionsBay 11-7082 acts as a selective inhibitor for nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome pathway. In addition, to the inhibition of nuclear factor-kappa B (NF-kB), Bay 11-7082 also triggers apoptosis in anucleated erythrocytes, human T-cell leukemia virus type I (HTLV-I)-infected T-cell lines and primary adult T-cell leukemia cells.
Enzyme inhibitorThis protein kinase inhibitor (FW = 207.31 g/mol; CAS 19542-67-7; lmax = 251 nm), also named 3-[(4-methylphenyl)sulfonyl]-(2E)-propenenitrile, targets NF-κB activation, selectively and irreversibly blocking TNF-α- induced phosphorylation of IκB-α without affecting phosphorylation of constitutive IκB-α. Mechanism of Inhibitory Action: NF-κB transcription factor regulates expression of inflammatory cytokines, various chemokines and immunoreceptors, as well as cell adhesion molecules. When stationed within the cytoplasm, NF-κB is kept inactive through its binding to the inhibitory factor IκB; however, certain stimuli result in IκB phosphorylation and ubiquitin-mediated degradation, freeing NF-κB for translocation to the nucleus. In endothelial cells, IκB-α phosphorylation and degradation occur within 15 min of TNFα treatment, allowing NF-κB to translocate to the nucleus to activate gene expression. Treatment of humnan vascular endothelial cells (HUVEC) with TNFα results in rapid loss of IκB-α from the cytoplasm. BAY11-7082 stabilizes IκB-α in a dose-dependent manner (IC50 ≈ 10 μM). There is a clear correlation between the concentration of drug that stabilizes IκB-α, the concentration that inhibits nuclear levels of NF-κB, and the concentration that inhibits adhesion molecule expression. More recent studies demonstrate that BAY 11- 7082 prevents ubiquitin conjugation to Ubc13 and UbcH7 by forming a covalent adduct with their cysteine residues via Michael addition at the C-3 atom of BAY 11-7082, followed by the release of 4-methylbenzenesulfinate. BAY 11-7082 stimulated Lys48-linked polyubiquitin chain formation in cells and protected Hypoxia-Inducible Factor-1α (HIF1α) from proteasomal degradation, suggesting it inhibits the proteasome. These results indicate that the anti-inflammatory effects of BAY 11-7082, its ability to induce B-cell lymphoma and leukemic T-cell death and to prevent the recruitment of proteins to sites of DNA damage are exerted via inhibition of components of the ubiquitin system– not by inhibiting NF-κB. BAY11-7082 also inhibits proliferation and promotes apoptosis in breast carcinoma MCF-7 cells by inhibiting phosphorylation of ATP citrate lyase.
storage+4°C
BackgroundBAY 11-7082 is a selective and irreversible inhibitor of cytokine-induced IκBα phosphorylation. Treatment with TNF-α leads to the activation of IκBα resulting in nuclear translocation of NF-κB where it regulates gene expression. Inhibition of IκBα phosphorylation leads to the inactivation of NF-κB. The effect that BAY 11-7082 has on proinflammatory cytokine production as it relates to the NF-κB/IκB kinase pathways makes it useful when studying inflammation. This compound inhibits IFN-α production and nuclear translocation of interferon regulatory factor 7 in human plasmacytoid dendritic cells, both important factors when studying immunotherapeutic strategies as they relate to autoimmune disorders. BAY 11-7082 inhibits TNF-α-induced surface expression of ICAM-1, VCAM-1, and E-Selectin in human endothelial cells with an IC50 value between 5–10 μM.
References[1] J W PIERCE. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo.[J]. The Journal of Biological Chemistry, 1997, 272 34: 21096-21103. DOI:10.1074/jbc.272.34.21096
[2] SIN-AYE PARK. 4-hydroxyestradiol induces anchorage-independent growth of human mammary epithelial cells via activation of IkappaB kinase: potential role of reactive oxygen species.[J]. Cancer research, 2009: 2416-2424. DOI:10.1158/0008-5472.can-08-2177
[3] RIE MIYAMOTO. Inhibitor of IkappaB kinase activity, BAY 11-7082, interferes with interferon regulatory factor 7 nuclear translocation and type I interferon production by plasmacytoid dendritic cells.[J]. Arthritis Research & Therapy, 2010, 12 3: R87. DOI:10.1186/ar3014
[4] CHUNMING XU. Bay11-7082 facilitates wound healing by antagonizing mechanical injury- and TNF-α-induced expression of MMPs in posterior cruciate ligament.[J]. Connective Tissue Research, 2019, 60 4: 311-322. DOI:10.1080/03008207.2018.1512978
[5] MIRI KIM. TNF-α induces human neural progenitor cell survival after oxygen–glucose deprivation by activating the NF-κB pathway[J]. Experimental and Molecular Medicine, 2018, 50 4: 1-14. DOI:10.1038/s12276-018-0033-1
Tag:BAY 11-7082(19542-67-7) Related Product Information
HELENALIN 5-Aminosalicylic acid MK-2206 2HCl 1,9-Pyrazoloanthrone PD 98059 SB 203580 Ruxolitinib LY 294002 Hydrochloride HMN-214 MS436 WITHAFERIN A ROCAGLAMIDE 6-AMINO-4-(4-PHENOXYPHENYLETHYLAMINO)QUINAZOLINE 3'-Hydroxyrocaglamide panepoxydone Rocaglamide I BAY 11-7085 BAY 11-7082